Clinical Trials

TAC T-cells for the Treatment of HER2-positive Solid Tumors (TACTIC-2)

TAC01-HER2 is a novel cell therapy that consists of genetically engineered autologous T cells expressing T-cell Antigen Coupler (TAC) that recognizes human epidermal growth factor receptor 2 (HER2). TAC directs T-cells to the targeted antigen (HER2), and once engaged with the target, activates them via the endogenous T cell receptor. This is an open-label, multicenter Phase 1/2 study that aims to establish safety, Maximum Tolerated Dose (MTD) or Recommended Phase 2 Dose (RP2D), pharmacokinetic profile and efficacy of TAC01-HER2 in subjects with relapsed or refractory solid tumors.

Contact us for more information on our trials.



    Read the Complete Clinical Trial Brief at ClinicalTrials.gov

    A Phase I/II Trial Investigating Safety and Efficacy of Autologous TAC-T Cells
    Targeting HER2 in Relapsed or Refractory Solid Tumors (TACTIC-2)

    Dose Escalation Phase

    Indications: HER2+ solid tumors (3+ HER2 expression)

    Status: Recruiting after Phase I completion

    Locations:

    MD Anderson Cancer Center in Houston, Texas

    Dana Farber Cancer Institute in Boston, Massachusetts

    University of Chicago Medical Center in Chicago, Illinois

    Dose Expansion Phase

    Indication cohorts:

    1) HER2+ breast cancer (3+ HER2 expression)

    2) HER2+ solid tumors other than breast cancer (3+ HER2 expression)

    3) HER2+ solid tumors including breast cancer (2+ HER2 expression)

    Status: Recruiting after Phase I completion

    Locations:

    MD Anderson Cancer Center in Houston, Texas

    Dana Farber Cancer Institute in Boston, Massachusetts

    University of Chicago Medical Center in Chicago, Illinois